The US Preventive Services Task Force recommends against initiating low-dose aspirin use for the primary prevention of cardiovascular disease (CVD) in adults 60 years or older. The decision to initiate low-dose aspirin use for the primary prevention of CVD in adults aged 40 to 59 years who have a 10% or greater 10-year CVD risk should be an individual one. Evidence indicates that the net benefit of aspirin use in this group is small. Persons who are not at increased risk for bleeding and are willing to take low-dose aspirin daily are more likely to benefit. This recommendation replaces the 2016 recommendation. The update is based on a systematic review on the effect of aspirin use on CVD and colorectal cancer and a microsimulation modeling study to assess the net balance of benefits and harms. Both CVD and bleeding risk increase with age. The benefits of initiating aspirin use are greater with higher CVD risk but become smaller with aging. Source: https://jamanetwork.com/
A U.S. randomized clinical trial found that 4:3 intermittent fasting (IMF) led to slightly greater…
A Danish nationwide cohort study provided real world evidence that both glucagon-like peptide 1 receptor…
A systematic review and meta-analysis of placebo-controlled randomized trials showed that there is moderate certainty…
A US cohort study indicated that statin use may reduce the risks of hepatocellular carcinoma…
A US cohort study suggests that carotid artery plaque (CAP) becomes very common with increasing…
A prospective US population-based cohort study suggested that higher intake of butter was associated with…
This website uses cookies.